The pill was licensed for adults 18 and older who have
tested positive for COVID-19 and have at least one risk factor for developing
severe disease, such as obesity or heart disease. Patients with
mild-to-moderate COVID-19 would take four pills of the drug, known
molnupiravir, twice a day for five days.
An antiviral pill that reduces symptoms and speeds recovery
could prove groundbreaking, easing caseloads on hospitals and helping to curb
outbreaks in poorer countries with fragile health systems. It would also
bolster the two-pronged approach to the pandemic: treatment, by way of
medication, and prevention, primarily through vaccinations.
Molnupiravir is also pending review with regulators in the
U.S., the European Union and elsewhere. The U.S. Food and Drug Administration
announced last month it would convene a panel of independent experts to
scrutinize the pill’s safety and effectiveness in late November.
Initial supplies will be limited. Merck has said it can
produce 10 million treatment courses through the end of the year, but much of
that supply has already been purchased by governments worldwide.
In October, U.K. officials announced they secured 480,000
courses of molnupiravir and expected thousands of vulnerable Britons to have
access to the treatment this winter via a national study.
“Today is a historic day for our country, as the U.K. is now
the first country in the world to approve an antiviral that can be taken at
home for COVID-19,” British health secretary Sajid Javid said.
“We are working at pace across the government and with the
NHS to set out plans to deploy molnupiravir to patients through a national
study as soon as possible,” he said in a statement, referring to the U.K.’s
National Health Service. Doctors said the treatment would be particularly
significant for people who don’t respond well to vaccination.
Merck and partner Ridgeback Biotherapeutic have requested
clearance for the drug with regulators around the world for adults with early
cases of COVID-19 who are at risk for severe disease or hospitalization. That’s
roughly the same group targeted for treatment with infused COVID-19 antibody
drugs, the standard of care in many countries for patients who don’t yet
require hospitalization.
Merck announced preliminary results in September showing its
drug cut hospitalizations and deaths by half among patients with early COVID-19
symptoms. The results haven’t yet been peer reviewed or published in a
scientific journal.
The company also didn’t disclose details on molnupiravir’s
side effects, except to say that rates of those problems were similar between
people who got the drug and those who received dummy pills.
The drug targets an enzyme the coronavirus uses to reproduce
itself, inserting errors into its genetic code that slow its ability to spread
and take over human cells. That genetic activity has led some independent
experts to question whether the drug could potentially cause mutations leading
to birth defects or tumors.
Britain’s Medicines and Healthcare products Regulatory
Agency said molnupiravir’s ability to interact with DNA and cause mutations had
been studied “extensively” and that it wasn’t found to pose a risk to humans.
“Studies in rats showed that (molnupiravir) may cause
harmful effects to the unborn offspring, although this was at doses which were
higher than those that will be given to humans, and these effects were not
observed in other animals,” the agency said in an email.
In company trials, both men and women were instructed to
either use contraception or abstain from sex. Pregnant women were excluded from
the study. Merck has stated that the drug is safe when used as directed.
Molnupiravir was initially studied as a potential flu
therapy with funding from the U.S. government. Last year, researchers at Emory
University decided to repurpose the drug as a potential COVID-19 treatment.
They then licensed the drug to Ridgeback and partner Merck.
Last week, Merck agreed to allow other drugmakers to make
its COVID-19 pill, in a move aimed at helping millions of people in poorer
countries get access. The Medicines Patent Pool, a U.N.-backed group, said
Merck will not receive royalties under the agreement for as long as the World
Health Organization deems COVID-19 to be a global emergency.
But the deal was criticized by some activists for excluding
many middle-income countries capable of making millions of treatments,
including Brazil and China.
Still, experts commended Merck for agreeing to widely share
its formula and promising to help any companies who need technological help in
making their drug — something no coronavirus vaccine producers have agreed to.
“Unlike the grotesquely unequal distribution of COVID-19
vaccines, the poorest countries will not have to wait at the back of the queue
for molnupiravir,” said Dr. Mohga Kamal-Yanni, a senior health adviser to the
People’s Vaccine Alliance. Fewer than 1% of the world’s COVID-19 vaccines have
gone to poor countries and experts hope easier-to-dispense treatments will help
them curb the pandemic.
The U.S. has agreed to pay roughly $700 per course of the
drug for about 1.7 million treatments. Merck says it plans to use a tiered
pricing strategy for developing countries. A review by Harvard University and
King’s College London estimated the drug costs about $18 to make each 40-pill
course of treatment.
While other treatments have been cleared to treat COVID-19,
including steroids and monoclonal antibodies, those are administered by
injection or infusion and are mostly used in hospitals and other health care
facilities.
Matthew Perrone reported from Washington. AP
0 comments:
Post a Comment